Prostate Neoplasms Clinical Trial
Official title:
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD) and the recommended Phase 2 dose of ASG-5ME in subjects with castration-resistant prostate cancer (CRPC).
The study has two components. The first aims to establish a safe dose of ASG-5ME. Once identified, the safety and preliminary estimate of antitumor activity of ASG-5ME will be tested in additional subjects with castration-resistant prostate cancer (CRPC) who are either chemotherapy naïve or chemotherapy exposed in expanded cohorts. ;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
Completed |
NCT01400555 -
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
Phase 1 | |
Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00643617 -
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
|
N/A | |
Recruiting |
NCT01581749 -
Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
|
Phase 4 | |
Completed |
NCT01424930 -
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT00544440 -
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
|
Phase 2 | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Suspended |
NCT02759744 -
Fusion Guided Focal Laser Ablation of Prostate Cancer
|
N/A | |
Completed |
NCT00474383 -
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
|
Phase 2 | |
Completed |
NCT01284920 -
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02319239 -
Prostate Cancer Stereotactic Radiotherapy
|
N/A | |
Completed |
NCT00910754 -
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT00972309 -
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
|
Phase 1 | |
Terminated |
NCT03531827 -
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
|
Phase 2 | |
Completed |
NCT00167648 -
Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05577689 -
Novel Therapy Target in Metastatic Prostate Cancer
|
||
Enrolling by invitation |
NCT03173924 -
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT04703543 -
Evaluating the Role of Both PSMA and 64Cu-PET/CT Total Body in Patients With Locally Relapsed Prostate Cancer
|
N/A | |
Completed |
NCT01477749 -
Sipuleucel-T Manufacturing Demonstration Study
|
Phase 2 |